FDA Alignment to Advance ProstACT Global Phase 3 Trial
Go back to FDA Alignment to Advance ProstACT Global Phase 3 Trial| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.80 -0.08 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.88 | 52 Week High | $2.18 | |||
| Open | $10.96 | 52 Week Low | $0.30 | |||
| Day High | $10.96 | P/E | N/A | |||
| Day Low | $10.73 | EPS | $-3.32 | |||
| Volume | 146,589 | |||||
| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.80 -0.08 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.88 | 52 Week High | $2.18 | |||
| Open | $10.96 | 52 Week Low | $0.30 | |||
| Day High | $10.96 | P/E | N/A | |||
| Day Low | $10.73 | EPS | $-3.32 | |||
| Volume | 146,589 | |||||



